Omeros (NASDAQ:OMER) VP Sells $463,500.00 in Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of Omeros stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Omeros Trading Up 1.3%

Shares of NASDAQ OMER opened at $19.11 on Friday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 14.93 and a beta of 2.60. Omeros Corporation has a 12 month low of $3.94 and a 12 month high of $19.65. The stock has a 50-day moving average price of $13.31 and a two-hundred day moving average price of $12.24.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, sell-side analysts predict that Omeros Corporation will post -0.37 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on OMER shares. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Trading of Omeros

Several institutional investors have recently modified their holdings of the business. State of Wyoming acquired a new stake in Omeros in the fourth quarter valued at $25,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Omeros in the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Omeros in the fourth quarter valued at about $33,000. Assetmark Inc. acquired a new stake in shares of Omeros in the first quarter valued at about $38,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 11,971 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.